Asaf Danziger is recorded as Board Member at NovoCure Ltd (NVCR) since January 1, 2012 and CEO at NovoCure Ltd (NVCR). The newest filing on record that lists Asaf Danziger as CEO and Board Member at NovoCure Ltd (NVCR) is dated April 20, 2026. NovoCure Ltd reported in an 8-K filed June 5, 2026 that Asaf Danziger was appointed director, effective June 3, 2026. NovoCure Ltd reported in an 8-K filed June 6, 2025 that Asaf Danziger was appointed director, effective June 4, 2025. NovoCure Ltd reported in an 8-K filed October 30, 2024 that Asaf Danziger retired as Chief Executive Officer (CEO), effective January 1, 2025. Equibles holds 7 filed executive changes naming Asaf Danziger; each is listed under recent activity with its source filing. The proxy statement of NovoCure Ltd reports total compensation of $1,539,088 for Asaf Danziger in fiscal 2024, including a base salary of $763,782. Disclosed compensation is on record for 8 fiscal years. Asaf Danziger has spoken on 18 earnings calls across 1 company, most recently for NovoCure Ltd on October 30, 2024. NovoCure Ltd is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at NovoCure Ltd includes David Hung (CEO and Board Member), Frank Leonard (CEO and Board Member), William Vernon (CEO and Board Member) and 7 others.
“The Company’s shareholders elected Asaf Danziger, William Doyle, Jeryl Hilleman, David Hung, Frank Leonard, Kinyip Gabriel Leung, Martin Madden, Allyson Ocean, Timothy Scannell, Kristin Stafford and William Vernon as directors, effective immediately, with a term expiring at the annual meeting of shareholders in 2027.”
“The Company's shareholders elected Ashley Cordova, Asaf Danziger, William Doyle, Jeryl Hilleman, David Hung, Kinyip Gabriel Leung, Martin Madden, Allyson Ocean, Timothy Scannell, Kristin Stafford and William Vernon as directors, effective immediately, with a term expiring at the annual meeting of shareholders in 2026.”
“When I joined Professor Palti, NovoCure was a company of a few people in a preclinical lab, working to bring TTFields therapy to the fight against cancer. Today, NovoCure is a team of more than 1,400 and is treating thousands of cancer patients across the globe.”
“As Bill mentioned, our third key objective this year is to deliver on the promise of our pipeline. This quarter, we made significant progress towards achieving that goal across our clinical programs in GPM, non-small cell lung cancer, and pancreatic cancer.”
“In Q1, we made strong progress advancing our clinical pipeline in three main indications. I will start with METIS. In March, we announced our Phase III METIS trial.”
“As Bill mentioned, we are focused on three objectives in 2024; grow our GBM business, launch lung cancer and deliver our pipeline. We have consolidated our clinical trial initiatives into three indications where we have proven efficacy and can address significant unmet needs.”
“Our GBM business is the core driver of our financial strength, generating $0.5 billion in revenue and free cash flow that are invested in the TTFields platform.”
